Picture of Divi's Laboratories logo

DIVISLAB — Divi's Laboratories News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

India's Divi's Labs slides on risk of generic versions of top drug

** Shares of Divi's Laboratories  DIVI.NS  fall 4.2% to
4,656 rupees, the most on the Nifty 50  .NSEI 
    ** Novartis  NOVN.S  loses initial bid to block generic
versions of its top-selling heart drug Entresto, for which
Divi's supplies pharma ingredients, or APIs
    ** Entresto is among largest drugs in Divi's portfolio and
generics could hurt FY27 EPS by 10%, says Kotak Institutional
Equities
    ** Adds: "We have not factored in a generic entry in
Entresto, which will hurt earnings, while valuations continue to
stay prohibitively expensive"
    ** Brokerage reiterates "sell" and a target price of 3,600
rupees, an implied downside of about 26%
    ** Analysts avg rating on DIVI is "hold"; median target
price is 4,437.50 rupees apiece --LSEG data

 (Reporting by Bharath Rajeswaran in Bengaluru)
 ((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))

Recent news on Divi's Laboratories

See all news